The corruption of Vanderbilt University, their sabotage of Hydroxychloroquine, and their financial gain from Remdesivir.

Designed to FAIL: Vanderbilt University's role in the Plandemic

I remember in the early 2000’s, Vanderbilt University was one of prestige.  Their nursing program, CNRA school, med school, etc were so exceptional  that many coveted an acceptance letter into their programs.  Their medical center was cutting edge technology in research.  They were not an “Ivy League” so tuition was reasonable with a fantastic education.

How the mighty take a tumble.

The story of Vanderbilt is one for the record books.  It started off way before covid, when they were in trouble for Medicare/Medicaid incident reporting.  They terminated a nurse in order to save themselves from the grievous mistake they had made that was on par with insurance fraud of the federal and state government.  Employees on the inside started rumblings about staffing issues, unsafe patient conditions, etc.  The state of Tennessee pressing charges against RaDonda Vaught, the Vanderbilt nurse who made a medication error, who reported the hospital was having major issues with their Pyxis machine drug dispensing program.  Why did Vanderbilt not stand up for THAT nurse?  She willingly admitted to the medication error she made, she self reported error, the hospital did not protect her, they severed employment to save themselves.

Throughout 2022, we have had the Vanderbilt gender dysphoria clinic where they were giving puberty blockers to young children, performing sex changing surgical procedures.  On YOUNG children.  If you want to learn more about that, research Matt Walsh.  Walsh and Tennessee state legislators got that clinic shut down “indefinitely”.

Based on the above shenanigans of Vanderbilt, we should not be surprised that they also had a hand in derailing early treatment for covid, namely Hydroxychloroquine.

And now we have the article I posted above from Charles Wright’s Substack.

In March 2020, permission was given to trial HCQ for the treatment of covid to prevent hospitalization.  We had a national stockpile of HCQ.  The goal was to give HCQ to patients at the onset of the virus to slow it in its tracks and prevent serious illness.  Alex Azar, Janet Woodcock, and Rick Bright all gave consent to trail HCQ on covid patients, but with a caveat.  They could only trial it in a HOSPITAL, on patients already HOSPITALIZED with covid.  Doesn’t that defeat the whole purpose of early treatment?  Deploying HCQ at first signs of illness or covid positive test?  Wait until they are so sick they require hospitalization?  (Hint, this trial was designed to fail and run HCQ through the mud).

On April 2, 2020, Vanderbilt said that they enrolled the first patients in ORCHID. Vanderbilt University Medical Center: "The ORCHID trial ... funded by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health, enrolled its first patient on April 2 and will include hundreds of patients to determine if hydroxychloroquine is an effective treatment against the virus projected to hospitalize thousands of U.S. residents in the coming weeks."

The screenshot below is from a press release that was included in email correspondence included in the FOIA request of Judicial Watch. I still have some questions about the funding and origins of the ORCHID trials, but they were clearly associated with the NIH at Vanderbilt.

On April 6, 2020, Katie Pavlich published "Thousands of Doctors: Yes, Hydroxychloroquine Works Against Wuhan Coronavirus" on Townhall. "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients. ... Dr. Mohammud Alam, an infectious disease specialist affiliated with Plainview Hospital, said 81 percent of infected covid patients he treated at three Long Island nursing homes recovered from the contagion.

On April 24, 2020, FDA issued a Drug Safety Communication (DSC) cautioning against the use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of arrhythmias. The DSC described reports of serious cardiac events, including QT prolongation, in patients receiving hydroxychloroquine or chloroquine, often in combination with azithromycin and other QT prolonging medicines, for the prevention or treatment of COVID-19. FDA Review HCL & Chloroquine. The FDA is cautioning against the same thing the NIH is testing, azithromycin, at this point.

On April 29, 2020, Anthony Fauci praised very weak results of a Remdesivir study. Anthony Fauci: "The data shows that Remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery. ... If you look at the time to recovery being shorter in the Remdesivir arm, it was 11 days compared to 15 days.  On April 29, 2020, Ralph Baric said that the results of the Remdesivir clinical trial was a "game changer." Note that UNC claimed they developed Remdesivir at the University of North Carolina. "Remdesivir was developed through an academic-corporate partnership between Gilead Sciences and the Baric Lab at the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health." That's extremely misleading, and distracts from Vanderbilt's role in developing Remdesivir. This UNC press release distracts from Vanderbilt's financial and academic conflict of interest in testing HCL in their ORCHID trials. 

So to recap here.  Vanderbilt is financially in bed with Fauci and Baric to make sure Remdesivir is the DRUG OF CHOICE.  So what better place to trial HCQ and make sure it fails than……Vanderbilt.

On May 1, 2020, the FDA granted and Emergency Use Authorization for Remdesivir. FDA.gov EUA Remdesivir. "While there is limited information known about the safety and effectiveness of using remdesivir to treat people in the hospital with COVID-19, the investigational drug was shown in a clinical trial to shorten the time to recovery in some patients."

On June 15, 2020, the FDA revoked their Emergency Use Authorization for HCL and chloroquine. fda.gov/media/138945. They said "Today’s request to revoke is based on new information, including clinical trial data results." Presumably this new information from the clinical trial data was from Vanderbilts' ORCHID study, which was shut down a few days later, based on some undisclosed "conditional power analysis." Among other things, the FDA said: "We now believe that the suggested dosing regimens for CQ and HCQ as detailed in the Fact Sheets are unlikely to produce an antiviral effect."  On June 19, 2020, the NHI stopped the ORCHID trial of HCL at Vanderbilt. They said that this was "based on conditional power analysis." I have a lot of questions about this. First of all, I can't tell if the sample size of patients tested was 20, or 475, or some other number. When they say, "even if we enrolled twice the number of patients," it seems more likely in that context that they were discussing increasing the trial size from 20 to 40 patients, rather than 475 to 950, as increasing the scope in this quantity this would seemingly take another award.

On June 20, 2020, Anthony said he was not surprised at the decision to stop ORCHID. He said their recommendations (presumably against HCL) could be made on "solid science" now. This is deceptive, designed-to-fail science, not solid science. Solid science would be to use Zinc with the HCL and publish the results. This is sabotage to promote the NIH-developed Remdesivir, among other motives.

So what level of dirty was Vanderbilt in the creation of Remdesivir?  It is best to think of Baric and UNC as a satellite of Vanderbilt and Mark Denison, in my opinion. Mark Denison and Ralph Baric are long-standing research partners. Denison's research precedes Baric's. Any way you want to look at it, Vanderbilt had a huge financial conflict of interest in conducting clinical trials of HCL.

November 12, 2012: Vanderbilt University Medical Center: A collaborative study, published Nov. 11 in Nature Medicine, demonstrates a SARS-coronavirus, altered to lack the ability to “proofread” (correct mistakes in replication), begins to mutate much more rapidly and becomes unable to cause disease in mouse models. In effect, the alteration creates a profoundly weakened or attenuated SARS virus. ... The study is the culmination of more than a decade of collaboration between the laboratories of Mark Denison, M.D., Craig-Weaver Professor of Pediatrics and professor of Pathology, Microbiology & Immunology at Vanderbilt University School of Medicine, and Ralph Baric, Ph.D., professor of Microbiology, Immunology and Epidemiology at the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health. ... Denison’s lab developed the attenuated SARS virus by disabling a unique exoribonuclease (or ExoN) protein, referred to as a proofreading protein. Previous Vanderbilt studies had shown that disabling ExoN knocks out the virus’s ability to correct mistakes, increases mutations twentyfold, and stops its ability to cause disease, at least in the lab setting. 

December 14, 2020: Vanderbilt.edu: Vanderbilt Chancellor Daniel Diermeier remarked: “The Denison Lab led the development of the COVID-19 antiviral remdesivir, which was for many months the only widely available and known treatment for COVID-19. He (Mark Denison) also was the first to show human antibody response to the Moderna vaccine.”

See why HCQ was sabotaged now?  The Remdesivir gang had too much money to lose for HCQ to work.  So they intentionally gave it with azithromycin, to show QTC prolongation, as two inhibitor medications could do, limit the investigation to hospitalized patients and not healthier outpatients, and stop the drug from being used.  They went so far as to telling pharmacies to not fill the drug.

Vanderbilt should be shuttered and closed for their role in this dirty game with peoples lives.  On many levels.